These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Efficacy and safety of varenicline for smoking cessation. Hays JT; Ebbert JO; Sood A Am J Med; 2008 Apr; 121(4 Suppl 1):S32-42. PubMed ID: 18342165 [TBL] [Abstract][Full Text] [Related]
5. Suicidal behavior and depression in smoking cessation treatments. Moore TJ; Furberg CD; Glenmullen J; Maltsberger JT; Singh S PLoS One; 2011; 6(11):e27016. PubMed ID: 22073240 [TBL] [Abstract][Full Text] [Related]
6. Use of varenicline versus bupropion and risk of psychiatric adverse events. Pasternak B; Svanström H; Hviid A Addiction; 2013 Jul; 108(7):1336-43. PubMed ID: 23445269 [TBL] [Abstract][Full Text] [Related]
7. Weighing up the risks and benefits of smoking cessation therapies. Bland P Practitioner; 2013; 257(1766):5. PubMed ID: 24555254 [No Abstract] [Full Text] [Related]
8. Varenicline (Chantix) warnings: risk versus benefit. Med Lett Drugs Ther; 2008 Jul; 50(1290):53. PubMed ID: 18617873 [No Abstract] [Full Text] [Related]
9. Rapid assessment of cardiovascular risk among users of smoking cessation drugs within the US Food and Drug Administration's Mini-Sentinel program. Toh S; Baker MA; Brown JS; Kornegay C; Platt R; JAMA Intern Med; 2013 May; 173(9):817-9. PubMed ID: 23529063 [No Abstract] [Full Text] [Related]
10. Cardiovascular and mortality risks in older Medicare patients treated with varenicline or bupropion for smoking cessation: an observational cohort study. Graham DJ; By K; McKean S; Mosholder A; Kornegay C; Racoosin JA; Young J; Levenson M; MaCurdy TE; Worrall C; Kelman JA Pharmacoepidemiol Drug Saf; 2014 Nov; 23(11):1205-12. PubMed ID: 25044169 [TBL] [Abstract][Full Text] [Related]
11. Smoking cessation in patients with chronic kidney disease. Raymond CB; Naylor HK CANNT J; 2010; 20(4):24-9; quiz 30-1. PubMed ID: 21319580 [No Abstract] [Full Text] [Related]
12. Treatment of nicotine dependence with Chantix (varenicline). Rankin KV; Jones DL Tex Dent J; 2011 May; 128(5):457-61. PubMed ID: 21834368 [TBL] [Abstract][Full Text] [Related]
13. Practical implementation of varenicline as an aid to smoking cessation in clinical practice. Tonstad S Pneumologia; 2009; 58(3):167-74. PubMed ID: 19817313 [TBL] [Abstract][Full Text] [Related]
14. The risk of adverse cardiovascular events from varenicline balanced against the benefits in mortality from smoking cessation. Kistler CE; Goldstein AO Nicotine Tob Res; 2012 Dec; 14(12):1391-3. PubMed ID: 22422928 [No Abstract] [Full Text] [Related]
15. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Nides M; Oncken C; Gonzales D; Rennard S; Watsky EJ; Anziano R; Reeves KR Arch Intern Med; 2006 Aug 14-28; 166(15):1561-8. PubMed ID: 16908788 [TBL] [Abstract][Full Text] [Related]
17. New reports examine psychiatric risks of varenicline for smoking cessation. Kuehn BM JAMA; 2012 Jan; 307(2):129-30. PubMed ID: 22235073 [No Abstract] [Full Text] [Related]
18. [Effectiveness and safety of varenicline for smoking cessation]. Christalla P; Dewenter M; El-Armouche A Dtsch Med Wochenschr; 2012 May; 137(18):940-4. PubMed ID: 22492478 [TBL] [Abstract][Full Text] [Related]
19. Safety of varenicline in patients with cardiovascular disease. Haber SL; Boomershine V; Raney E J Pharm Pract; 2014 Feb; 27(1):65-70. PubMed ID: 24080536 [TBL] [Abstract][Full Text] [Related]